Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1337)	11/14/2001 11:36:34 AM
From: William Partmann	Read Replies (2) \| Respond to of 10345

This is not up to date but it's the best I've seen. My thanks to biopharma for the link. biospace.com

To: Icebrg who wrote (1337)	11/21/2001 6:16:21 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

While not directly concerning Elan, the following piece of news might anyhow be considered as a vote of confidence in a technology of interest to Elan. Inex Pharma Stk Up 9% On Second 'Surprise' Pact By ANDY GEORGIADES Of DOW JONES NEWSWIRES TORONTO -- Inex Pharmaceuticals Corp. (T.IEX) pleasantly surprised investors again Tuesday, announcing its second pact with a big multinational pharmaceutical company in less than a year. In Toronto, the stock has gained 54 Canadian cents, or 9%, to C$6.54 on about 455,000 shares. As reported, Inex announced a licensing deal with GlaxoSmithKline PLC (GSK) to encapsulate Glaxo's camptothecin anti-cancer agents inside Inex's Transmembrane Carrier System (TCS), a drug-delivery technology. The deal includes up to C$57 million in upfront and milestone payments. Earlier this year, Inex signed a C$60 million joint venture with Elan Corp.(ELN) for the commercialization of Onco TCS, its lead product anti-cancer product, currently in eight clinical trials. "Our scientists are always evaluating different drugs that they think would be good candidates inside our delivery technology," David Main, president and chief executive of Inex, told Dow Jones. Inex investigated Glaxo's camptothecin class of compounds because they were among the few approved cell cycle inhibitors, which are more effective if kept at the tumor site longer, but are unstable in the bloodstream. So far, the evidence shows TCS increases the compound's efficacy. "We shared the data with them and they got pretty excited," Main said. "We then entered into a confidential research collaboration with their scientists, who tested it themselves, and they came back and said we've got to move this ahead." Main called the pacts with Elan and GSK complementary, with the former restricted to vincristine, and the latter restricted to the camptothecin class. "There's no overlap whatsover in terms of the drugs, and it also still leaves us lots of opportunities to develop our own products outside of those two drugs, or to work with others," he said. While Inex is responsible for the "upfront work," Glaxo is responsible for all the clinical and regulatory development. The company is moving forward with a second drug-delivery technology platform, OligoVax, which Main said has "blockbuster potential." "I can see bringing partners on board to assist with that technology, but we certainly have the capabilities to move it ahead independently," he said. Company Web Site: inexpharm.com